GSA Capital Partners LLP increased its stake in shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 55.8% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 92,395 shares of the company’s stock after buying an additional 33,100 shares during the period. GSA Capital Partners LLP owned 0.14% of Aralez Pharmaceuticals worth $305,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $100,000. Goldman Sachs Group Inc. acquired a new position in shares of Aralez Pharmaceuticals during the first quarter worth about $109,000. LMR Partners LLP acquired a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $145,000. FNY Managed Accounts LLC boosted its position in shares of Aralez Pharmaceuticals by 73.3% in the second quarter. FNY Managed Accounts LLC now owns 52,000 shares of the company’s stock worth $172,000 after buying an additional 22,000 shares during the last quarter. Finally, Geode Capital Management LLC acquired a new position in shares of Aralez Pharmaceuticals during the first quarter worth about $273,000. Hedge funds and other institutional investors own 49.63% of the company’s stock.
Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down 2.57% during midday trading on Tuesday, hitting $4.92. 595,524 shares of the stock were exchanged. The stock’s market cap is $320.99 million. Aralez Pharmaceuticals Inc. has a one year low of $3.10 and a one year high of $8.59. The stock’s 50-day moving average price is $5.20 and its 200 day moving average price is $4.14.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to the consensus estimate of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The business’s quarterly revenue was up 142.3% compared to the same quarter last year. On average, analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.05) earnings per share for the current year.
A number of equities analysts have issued reports on the stock. Guggenheim restated a “buy” rating and set a $12.00 target price on shares of Aralez Pharmaceuticals in a research report on Monday, August 15th. Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Aralez Pharmaceuticals in a research report on Friday, September 16th.
In other news, Director Robert Paul Harris sold 150,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the transaction, the director now owns 669,094 shares in the company, valued at $3,894,127.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.77% of the company’s stock.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.